Ruili Zhang

Ruili Zhang

Auto-generated profile, based on publicly available information

Ruili Zhang

State Key Laboratory of Medicinal Chemical Biology

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 July 2022 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
YWYu Wei
Yu Wei
RZRuili Zhang
Ruili Zhang
XLXiaoqiang Li
Xiaoqiang Li
ZLZhonglin Li
Zhonglin Li
KGKaimin Guo
Kaimin Guo
YHYUNHUI HU
YUNHUI HU
Diabetic retinopathy (DR), a diabetic microangiopathy caused by diabetes, affects approximately 93 million people, worldwide. However, the drugs used to treat DR have limited efficacy and the variety of side effects. This is possibly because the complicated pathogenesis of DR is associated with multiple proteins. In this work, we attempted to identify potential drugs against DR‐associated proteins and predict potential targets for drugs using in silico prediction of chemical‐protein interactions (CPI) based on multitarget quantitative structure‐activity relationship (mt‐QSAR) method. Therefore, we developed 128 binary classifiers to predict the CPI for 15 DR targets using random forest (RF), k‐nearest neighbours (KNN), support vector machine (SVM), and neural network (NN) algorithms with MACCS, extended connectivity fingerprints (ECFP6) fingerprints, and protein descriptors. In order to facilitate discovery of the novel drugs and target identification using the 128 binary classifiers, a free web server (DRDB) was developed. Compound Danshen Dripping Pills (CDDP), composed of Salvia miltiorrhiza, Panax notoginseng, and borneol, is commonly used in the treatment of cardiovascular diseases. To explore the applicability of DRDB, the potential CPIs of CDDP in treatment of DR were investigated based on DRDB. In vitro experimental validation demonstrated that cryptotanshinone and protocatechuic acid, two key components of CDDP, are capable of targeting ICAM‐1 which is one of the key target of DR. We hope that this work can facilitate development of more effective clinical strategies for the treatment of DR.